EI

274.5

+1.44%↑

MRK1

107.75

+0.19%↑

SAN

80.12

+0.88%↑

SHL.DE

47.33

0%↓

UCB

202.5

-0.59%↓

EI

274.5

+1.44%↑

MRK1

107.75

+0.19%↑

SAN

80.12

+0.88%↑

SHL.DE

47.33

0%↓

UCB

202.5

-0.59%↓

EI

274.5

+1.44%↑

MRK1

107.75

+0.19%↑

SAN

80.12

+0.88%↑

SHL.DE

47.33

0%↓

UCB

202.5

-0.59%↓

EI

274.5

+1.44%↑

MRK1

107.75

+0.19%↑

SAN

80.12

+0.88%↑

SHL.DE

47.33

0%↓

UCB

202.5

-0.59%↓

EI

274.5

+1.44%↑

MRK1

107.75

+0.19%↑

SAN

80.12

+0.88%↑

SHL.DE

47.33

0%↓

UCB

202.5

-0.59%↓

Search

Laboratorios Farmaceuticos Rovi SA

Suletud

SektorTervishoid

58.65 -1.18

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

58.25

Max

59.55

Põhinäitajad

By Trading Economics

Sissetulek

3.9M

27M

Müük

4.8M

160M

P/E

Sektori keskmine

23.127

35.293

Aktsiakasum

0.423

Dividenditootlus

1.54

Kasumimarginaal

16.767

Töötajad

2,188

EBITDA

4.2M

35M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+36.11% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.54%

3.07%

Järgmine tulemuste avaldamine

6. nov 2025

Turustatistika

By TradingEconomics

Turukapital

242M

3.1B

Eelmine avamishind

59.83

Eelmine sulgemishind

58.65

Uudiste sentiment

By Acuity

56%

44%

316 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. sept 2025, 23:56 UTC

Kuumad aktsiad

Stocks to Watch: FedEx, 22nd Century, Scholastic

18. sept 2025, 22:01 UTC

Suurimad hinnamuutused turgudel

22nd Century Group Shares Gain on Debt Repayment, New Capital

18. sept 2025, 20:51 UTC

Omandamised, ülevõtmised, äriostud

UPS Terminates Plan to Buy Estafeta

18. sept 2025, 20:31 UTC

Tulu

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18. sept 2025, 20:26 UTC

Tulu

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18. sept 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. sept 2025, 23:43 UTC

Market Talk

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18. sept 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

18. sept 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Cautious Mood -- Market Talk

18. sept 2025, 23:31 UTC

Market Talk

FedEx Says U.S. Demand Is Resilient -- Market Talk

18. sept 2025, 22:03 UTC

Tulu

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18. sept 2025, 22:01 UTC

Tulu

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18. sept 2025, 21:56 UTC

Tulu

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18. sept 2025, 21:54 UTC

Tulu

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18. sept 2025, 21:48 UTC

Tulu

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18. sept 2025, 21:47 UTC

Tulu

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18. sept 2025, 21:17 UTC

Tulu

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18. sept 2025, 21:07 UTC

Tulu

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18. sept 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. sept 2025, 20:50 UTC

Market Talk
Tulu

Financial Services Roundup: Market Talk

18. sept 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

18. sept 2025, 20:22 UTC

Omandamised, ülevõtmised, äriostud

UPS Cites Inability of All Closing Conditions to Be Satisfied

18. sept 2025, 20:22 UTC

Omandamised, ülevõtmised, äriostud

United Parcel Service Terminates Plan to Buy Estafeta

18. sept 2025, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18. sept 2025, 20:18 UTC

Tulu

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18. sept 2025, 20:18 UTC

Tulu

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18. sept 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. sept 2025, 20:07 UTC

Tulu

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18. sept 2025, 20:03 UTC

Tulu

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

36.11% tõus

12 kuu keskmine prognoos

Keskmine 80.85 EUR  36.11%

Kõrge 90 EUR

Madal 71.7 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

51.1 / N/AToetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

316 / 371 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat